The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The CONSA consortium: advancing newborn screening & early intervention for SCD in SSA
Enrico Novelli, MD, MS, University of Pittsburgh, Pittsburgh, PA, discusses the CONSA consortium, launched by the American Society of Hematology (ASH) to address challenges in sickle cell disease (SCD). The consortium focuses on advancing newborn screening and early intervention across seven countries of sub-Saharan Africa (SSA), aiming to demonstrate the effectiveness of such programs and encourage public health interventions on a larger scale. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisor/consultant for Novo Nordisk, Chiesi Pharmaceuticals and Shield Therapeutics.
